Cytyc's ThinPrep 2000 Processor contributes to expanded role of fine-needle aspiration biopsy (FNAB) in breast cancer detection.MARLBOROUGH, Mass.--(BUSINESS WIRE)--Aug. 7, 1995--The ThinPrep 2000 Processor, an advanced cytology cytology (sītŏl`əjē), in biology, the study of the structure of all normal and abnormal components of cells and the changes, movements, and transformations of such components. preparation system recently introduced by Cytyc Corp., is making a significant contribution to the diagnostic accuracy of fine-needle aspiration biopsy aspiration biopsy n. See needle biopsy. Aspiration biopsy The removal of cells in fluid or tissue from a mass or cyst using a needle for microscopic examination and diagnosis. (FNAB FNAB Fine Needle Aspiration Biopsy FNAB Fédération National de l'Agriculture Biologique ), a technique used with increasing frequency to detect breast cancer. The ThinPrep 2000 utilizes unique automated technology to collect, preserve, and prepare slides of human cells for accurate microscopic screening and diagnosis. The incidence of breast cancer is widespread, and it is estimated that one in every nine women in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. will develop breast cancer during her lifetime. Breast cancer is the leading cause of cancer death in women between the ages of 20 and 54 and is the second most common form of the disease among women in the 55 to 75 age group. Early disease detection and treatment provide the best options for long-term survival. Fine-needle aspiration biopsy, physical examination and mammography mammography, diagnostic procedure that uses low-dose X rays to detect abnormalities in the breasts. The early diagnosis of breast cancer made possible by the routine use of mammography for screening women increases a woman's treatment alternatives and improves her , comprise a diagnostic triad known as the Triple Test. The Triple Test has been shown to be an effective methodology for detecting breast disease without subjecting the woman to the trauma of surgery. And, while the presence of a palpable mass in the breast certainly requires examination by a physician, more than 80 percent of the estimated 560,000 open surgical biopsies performed annually in the United States are benign. FNAB can help avoid unnecessary testing and expedite referral to the appropriate physician for definitive evaluation and treatment. "Of our 836 breast FNABs last year, 640 were benign diagnoses. Many of these patients were spared surgical biopsies. The cost and human savings are substantial," states Kathy Richard, a cytotechnologist cy·to·tech·nol·o·gist n. A technician trained in medical examination and identification of cellular abnormalities. cytotechnologist a medical laboratory technologist specializing in cytology. at Greater Springfield Pathology in Springfield, Mass. FNAB offers several important clinical and patient advantages in the detection of breast disease. The technique requires no anesthetic anesthetic Agent that produces a local or general loss of sensation, including pain, and therefore is useful in surgery and dentistry. General anesthesia induces loss of consciousness, most often using hydrocarbons (e.g. and can be performed in the doctor's office. Patients experience minimal discomfort and the test is simple to perform, safe and accurate. Results are available within a few hours, often making it possible to provide the patient with a diagnosis during the first office visit. In the event of cancer detection, FNAB allows the physician to discuss treatment alternatives with the woman without delay and provides surgeons with important preoperative pre·op·er·a·tive adj. Preceding a surgical operation. preoperative preceding an operation. preoperative care the preparation of a patient before operation. information. Until recently, the quality of the preparation of FNABs could compromise or prevent interpretation by a cytopathologist. Conventional slide preparation methods frequently resulted in specimens that were difficult to interpret or completely unsatisfactory for evaluation. The introduction of the ThinPrep 2000 System has virtually eliminated these problems. The System optimizes slide preparation to produce an unusually clear view of human cells that facilitates an accurate and cost-effective diagnosis. "Utilizing the ThinPrep 2000 for breast FNAB, clinicians can achieve maximum cell recovery and the highest quality preparation of the cells. This minimizes unsatisfactory and false negative specimens. The ThinPrep 2000 System is far superior to any other system or method of slide preparation," explains Bruce Dziura, M.D., a pathologist at Greater Springfield Pathology. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. Kathy Richard, "With the ThinPrep 2000, we can get the FNAB result to the patient's physician within hours, versus possibly weeks with a biopsy. This expedites diagnosis by eliminating the time delay associated with visiting another physician, scheduling a biopsy, undergoing the procedure and waiting for the results." The increased diagnostic confidence of breast FNAB has resulted in a significant increase in the number of procedures performed. "FNAB is a great diagnostic test. Utilizing the ThinPrep 2000 System, it is easy for clinicians to take a specimen, send it to our lab for analysis and receive a definitive diagnosis," states Dr. Dziura. The ThinPrep 2000 Cytology Preparation System is the newest version of Cytyc Corporation's proprietary technology for optimizing preparation of cytology specimens. The new ThinPrep 2000 platform incorporates the company's unique cell dispersion and filtration technology, setting a new standard inn cytology preparation and diagnosis. Founded in 1987, Cytyc Corporation is a leading innovator in the development of automated cytology products. With corporate headquarters located in Marlborough, Mass., the company is in the process of conducting a multi-center Pap smear Pap smear or Papanicolaou smear Sample of cells from the vagina and cervix of the uterus for laboratory staining and examination to detect genital herpes and early-stage cancer, especially of the cervix. Developed by the Greek-born U.S. clinical trial utilizing the ThinPrep 2000 Processor. The data from this clinical trial will form the basis of the company's premarket approval premarket approval Medical devices A scientific and regulatory review by the FDA to ensure the safety and effectiveness of a Class III device, before its approval for marketing. See Advisory panel, Medical device. application to the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. . This application will be in support of the use of the ThinPrep System as an alternative to the Pap smear for the detection of cervical cancer Cervical Cancer Definition Cervical cancer is a disease in which the cells of the cervix become abnormal and start to grow uncontrollably, forming tumors. . -0- Photography illustrating the microscopic benefits of ThinPrep FNABs are available upon request. CONTACT: Cytyc Corporation Dan Levangie/ Annette Marshall 800/442-9892 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion